Linked Life Data

15641479

Source:http://linkedlifedata.com/resource/pubmed/id/15641479

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15641479rdf:typepubmed:Citationlld:pubmed
pubmed-article:15641479lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:15641479lifeskim:mentionsumls-concept:C1512162lld:lifeskim
pubmed-article:15641479lifeskim:mentionsumls-concept:C0007137lld:lifeskim
pubmed-article:15641479lifeskim:mentionsumls-concept:C0460004lld:lifeskim
pubmed-article:15641479lifeskim:mentionsumls-concept:C0144576lld:lifeskim
pubmed-article:15641479lifeskim:mentionsumls-concept:C1522484lld:lifeskim
pubmed-article:15641479lifeskim:mentionsumls-concept:C0574032lld:lifeskim
pubmed-article:15641479lifeskim:mentionsumls-concept:C0036525lld:lifeskim
pubmed-article:15641479lifeskim:mentionsumls-concept:C0034897lld:lifeskim
pubmed-article:15641479lifeskim:mentionsumls-concept:C0220825lld:lifeskim
pubmed-article:15641479lifeskim:mentionsumls-concept:C0205390lld:lifeskim
pubmed-article:15641479lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:15641479pubmed:issue6lld:pubmed
pubmed-article:15641479pubmed:dateCreated2005-1-11lld:pubmed
pubmed-article:15641479pubmed:abstractTextPaclitaxel (24-hour infusion) has yielded activity in advanced squamous cell carcinoma of the head and neck (SCCHN). Protracted exposure to paclitaxel may overcome resistance observed by using shorter infusions. Therefore we sought to evaluate paclitaxel by 96-hour infusion in both treatment-naïve and previously treated patients with SCCHN.lld:pubmed
pubmed-article:15641479pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15641479pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15641479pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15641479pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15641479pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15641479pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15641479pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15641479pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15641479pubmed:languageenglld:pubmed
pubmed-article:15641479pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15641479pubmed:citationSubsetIMlld:pubmed
pubmed-article:15641479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15641479pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15641479pubmed:statusMEDLINElld:pubmed
pubmed-article:15641479pubmed:issn0735-7907lld:pubmed
pubmed-article:15641479pubmed:authorpubmed-author:Eastern...lld:pubmed
pubmed-article:15641479pubmed:authorpubmed-author:LiYiYlld:pubmed
pubmed-article:15641479pubmed:authorpubmed-author:ForastiereArl...lld:pubmed
pubmed-article:15641479pubmed:authorpubmed-author:LangerCorey...lld:pubmed
pubmed-article:15641479pubmed:authorpubmed-author:NairSureshSlld:pubmed
pubmed-article:15641479pubmed:authorpubmed-author:CohenRoger...lld:pubmed
pubmed-article:15641479pubmed:authorpubmed-author:JenningsTimot...lld:pubmed
pubmed-article:15641479pubmed:authorpubmed-author:DeContiRonald...lld:pubmed
pubmed-article:15641479pubmed:issnTypePrintlld:pubmed
pubmed-article:15641479pubmed:volume22lld:pubmed
pubmed-article:15641479pubmed:ownerNLMlld:pubmed
pubmed-article:15641479pubmed:authorsCompleteYlld:pubmed
pubmed-article:15641479pubmed:pagination823-31lld:pubmed
pubmed-article:15641479pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:15641479pubmed:meshHeadingpubmed-meshheading:15641479...lld:pubmed
pubmed-article:15641479pubmed:meshHeadingpubmed-meshheading:15641479...lld:pubmed
pubmed-article:15641479pubmed:meshHeadingpubmed-meshheading:15641479...lld:pubmed
pubmed-article:15641479pubmed:meshHeadingpubmed-meshheading:15641479...lld:pubmed
pubmed-article:15641479pubmed:meshHeadingpubmed-meshheading:15641479...lld:pubmed
pubmed-article:15641479pubmed:meshHeadingpubmed-meshheading:15641479...lld:pubmed
pubmed-article:15641479pubmed:meshHeadingpubmed-meshheading:15641479...lld:pubmed
pubmed-article:15641479pubmed:meshHeadingpubmed-meshheading:15641479...lld:pubmed
pubmed-article:15641479pubmed:meshHeadingpubmed-meshheading:15641479...lld:pubmed
pubmed-article:15641479pubmed:meshHeadingpubmed-meshheading:15641479...lld:pubmed
pubmed-article:15641479pubmed:meshHeadingpubmed-meshheading:15641479...lld:pubmed
pubmed-article:15641479pubmed:meshHeadingpubmed-meshheading:15641479...lld:pubmed
pubmed-article:15641479pubmed:meshHeadingpubmed-meshheading:15641479...lld:pubmed
pubmed-article:15641479pubmed:meshHeadingpubmed-meshheading:15641479...lld:pubmed
pubmed-article:15641479pubmed:meshHeadingpubmed-meshheading:15641479...lld:pubmed
pubmed-article:15641479pubmed:meshHeadingpubmed-meshheading:15641479...lld:pubmed
pubmed-article:15641479pubmed:year2004lld:pubmed
pubmed-article:15641479pubmed:articleTitlePhase II evaluation of 96-hour paclitaxel infusion in advanced (recurrent or metastatic) squamous cell carcinoma of the head and neck (E3395): a trial of the Eastern Cooperative Oncology Group.lld:pubmed
pubmed-article:15641479pubmed:affiliationFox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA. cj_langer@fccc.edulld:pubmed
pubmed-article:15641479pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15641479pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:15641479pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:15641479pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:15641479pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed